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Phosphorodiamidate  morpholino  oligonucleotides  (PMO)  are  used  as a promising  exon-skipping  gene
therapy  for  Duchenne  muscular  dystrophy  (DMD).  One  potential  complication  of high dose  PMO  therapy
is its  transient  accumulation  in the  kidneys.  Therefore  new  urinary  biomarkers  are  needed  to  monitor
this  treatment.  Here,  we  carried  out a pilot  proteomic  proﬁling  study  using  stable  isotope  labeling  in
mammals  (SILAM)  strategy  to  identify  new  biomarkers  to monitor  the effect  of  PMO  on  the kidneys  of
the dystrophin  deﬁcient  mouse  model  for DMD  (mdx-23).  We  ﬁrst  assessed  the  baseline  renal  status  of
the mdx-23  mouse  compared  to  the  wild  type  (C57BL10)  mouse,  and then  followed  the  renal  outcome
of  mdx-23  mouse  treated  with  a single  high  dose  intravenous  PMO  injection  (800  mg/kg).  Surprisingly,
untreated  mdx-23  mice  showed  evidence  of renal  injury  at baseline,  which  was  manifested  by albumin-
uria,  increased  urine  output,  and  changes  in  established  urinary  biomarker  of acute  kidney injury  (AKI).
The  PMO  treatment  induced  further  transient  renal  injury,  which  peaked  at 7 days,  and  returned  to almost
the  baseline  status  at 30 days  post-treatment.  In the  kidney,  the  SILAM  approach  followed  by  western
blot  validation  identiﬁed  changes  in  Meprin  A subunit  alpha  at day  2, then  returned  to  normal  levelseywords:
MO
rinary biomarkers
dx-23
uchenne muscular dystrophy
lusterin
at  days  7 and  30 after  PMO  injection.  In the urine,  SILAM  approach  identiﬁed  an  increase  in Clusterin
and  -glutamyl  transpeptidase  1  as potential  candidates  to monitor  the  transient  renal  accumulation
of  PMO.  These  results,  which  were  conﬁrmed  by  Western  blots  or ELISA,  demonstrate  the  value  of  the
SILAM  approach  to identify  new  candidate  biomarkers  of  renal  injury  in  mdx-23  mice  treated  with  high
dose  PMO.
© 2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
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ground (C57BL/10ScSn-Dmdmdx/J). Wild-type background strain
(C57BL/10) was  used as baseline control. All mice were purchased
from Jackson Laboratory, Bar Harbor, Maine.
Fig. 1. Overall study design. Mdx23 (n = 36) randomly divided two groups, one
group (n = 18) was  treated with a single high dose (800 mg/kg) and the second group
(n  = 18) was treated with the same volume of saline vehicle. Urine samples at days 1,
6,  and 29 urine while kidneys were collected at days 2, 7 and 30 following treatment
(n  = 6 per group and per time point). For SILAM proteome proﬁling of urine and kid-
ney samples one mouse was randomly selected from PMO and saline treated group
and  at each time point totaling 6 urine samples and 6 kidney samples for LC–MS/MS
analysis. Protein that were found differentially altered in kidney and urine samples
were further validated by western blotting for kidney extract and ELISA for urineA. Zhang et al. / Toxicolo
. Introduction
Therapeutic oligonucleotides have received sustained interest
ue to the high speciﬁcity to their mRNA or microRNA targets, and
ffectiveness in inhibiting their target [1,2]. Multiple chemistries
re under development with goals of optimizing cellular delivery,
fﬁnity and speciﬁcity for the target. As with most drugs, toxicity
ndings may  limit the doses of the oligonucleotides that can be
afely administered. Acute inﬂammatory reactions can be a dose-
imiting toxicity, but are observed with some chemistries such as
hosphorothioates (PSs) [3–5], but not others such as phosphoro-
iamidate morpholino oligonucleotides (PMO) [6]. Target organs
or oligonucleotide drugs typically include the liver and kidney,
here these drugs accumulate causing cellular toxicity prior to
eing metabolized and/or excreted by these tissues [7–9].
The large majority of oligonucleotide drugs utilize a PSs chem-
cal linkage between adjacent nucleotides. This linkage has been
hown to improve stability by reducing cleavage by nucleases. PSs
rugs also show strong pharmacokinetic and pharmacodynamic
roﬁles [10]. However, PSs drugs may  also show off-target pro-
ein binding and induction of complement or other inﬂammatory
athways. The PMO chemistry seems entirely resistant to nucle-
se cleavage, and shows no induction of inﬂammatory pathways at
ery high doses [6,11,12].
Clinical development of PMO  chemistry is most advanced
n applications to exon-skipping in Duchenne muscular dystro-
hy (DMD) [13–15]. DMD  is caused by dystrophin deﬁciency in
yoﬁbers, leading to plasma membrane instability. Overt breaches
f the dystrophin-deﬁcient myoﬁber membranes appear to provide
 delivery route for the PMO  drugs, thus bypassing the otherwise
apid clearance [16,17]. Pre-clinical studies conducted in murine
nd canine models for DMD  showed that systemic IV injection
f PMO  drug successfully restored the missing dystrophin pro-
ein in skeletal muscle with concomitant improved functional
utcomes [18–21]. Both biochemical and clinical efﬁcacy is dose
esponsive, with high doses (100–300 mg/kg/wk.) showing the
ost pronounced long-term therapeutic effects, a ﬁnding likely
elated to the presumed bulk ﬂow process of drug delivery across
nstable myoﬁber membranes.
Previous toxicity studies performed on the dystrophin deﬁcient
ouse model for DMD  (mdx-23) and monkeys [12], showed that
eekly injections of high doses of PMO  (960 mg/kg/wk in mice;
20 mg/kg/wk in monkeys), can induce transient renal tubular
njury. PMO  is accumulated in renal proximal tubular cells, in a
imilar manner to other oligonucleotide drugs [6]. From the renal
istological view, the accumulation of PMO  in renal tubules is
ssociated with ﬂattened tubular epithelium, basophilic granules,
nd mild tubular vacuolation [6,12]. These lesions, however, are
onsidered dose-dependent and potentially reversible [12]. There-
ore, because PMO appears a promising treatment for patients with
MD, it is necessary to further evaluate the effect of PMO  on kid-
eys and identify new urine biomarkers to monitor the renal PMO
oad and outcome for DMD  patients [22].
Urine is a readily accessible body ﬂuid and useful source for
iomarker discovery and assessment of the renal effects of cyto-
oxic drugs [23–27]. Here, we carried out a pilot proteome proﬁling
tudy to follow the renal outcome of the mdx-23 mouse after a
ingle intravenous injection of high dose PMO  (800 mg/kg). More
peciﬁcally, we analyzed kidney and urine proteomes collected
rom PMO  and saline treated mdx-23 mice using SILAM strategy in
ombination with high precision LC–MS/MS analysis of peptides,
nd bioinformatics mapping to parent proteins (supplemental Fig.
4). Subsequently, we veriﬁed the positive ﬁndings by Western
lots or ELISA assay using all mouse groups. This approach iden-
iﬁed an alterations in the levels Meprin A subunit alpha (Mep-1)
n the kidney and an increase of two urine accessible candidateorts 2 (2015) 838–849 839
biomarkers clusterin, and gamma  glutamytransferase 1 (GGT1)
(Fig. 1), that may  become a useful biomarker proﬁle to monitor
the renal outcome of patients treated with PMO and other oligonu-
cleotides.
2. Material and methods
2.1. Animal experiments
All experiments were reviewed and approved by the Insti-
tutional Animal Care and Use Committee (IACUC) of Children’s
National Medical Center (protocol # 199-01-07 for 15N labeled
SILAM [Stable isotope labeling by amino acids in mouse]; protocol
# 304-13-04 for toxicity test of PMO  oligonucleotide therapy).
The animal models used in this study included the mdx-
23 mouse model having a spontaneous DMD  gene mutation
causing a splice site mutation in exon 23 on the C57BL/10 back-samples (samples size n = 6 per group per time point); also urine candidates vali-
dated by ELISA (samples size n = 6 per group per time point). Mep-1 increased day 2
as  a, potential biomarker in kidney and clusterin increased day 1 and GGT1 increased
day 6, decreased at day 29 as potential urinary biomarkers which associated with
PMO  kidney loading and clearance.
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.2. 15N labeled mouse
A previously reported stable isotope labeling in mammals
SILAM) strategy was used to generate a stock of 15N-labeled tissue
nd body ﬂuids proteome atlases as an internal standard for accu-
ate proteome proﬁling experiments [28,29]. Brieﬂy, 3 week old
57BL6 male were fed a chow of 15N enriched Spirulina (Mouse-
xpress, 15N = 98%; Cambridge Isotope Laboratories, Andover, MA).
abeling efﬁciency of urine proteins was monitored weekly using
ass spectrometry analysis and Integrated Proteomics Pipeline
ool (IP2 version 1.42). Sufﬁcient urinary proteome labeling with
5N was deﬁned as >95% of peptides showing full labeling with the
eavy isotope 15N, and this level was reached by 12 weeks of feed-
ng 15N enriched Spirulina (supplemental Fig. S2). Both 15N labeled
rine protein and15N-labeled kidney proteins were used as internal
o proﬁle protein in urine and kidneys of PMO  treated and untreated
dx-23 mice as described below.
.3. Study design
Seven-week-old mdx-23 male mice (n = 36) were randomly
ivided into two groups and each mouse was ear tagged with spe-
iﬁc ID number for follow up studies. Each mouse in the PMO
reated group (n = 18) was injected with a single high dose PMO
800 mg/kg dissolved in 200 L saline solution, AVI-4225, GGC CAA
CC TCG GCT TAC CTG AAA T) via a retro-orbital vein while the
ontrol group (n = 18) was injected with 200 L saline vehicle. Base-
ine urine samples were collected from each mdx-23 mouse before
reatment with PMO or saline solution then at 30 min, 45 min,
0 min, 90 min, 120 min, 180 min  and 360 min  post-treatment.
hese urine samples were used for PMO  urinary PK. Further urine
amples were collected for a period of 4 h at days 1, 6, 14, 20 and
9 post-treatment, and randomly selected one mouse sample at
ays 1, 6 and 29 just before sacriﬁced mice from each group used
or proteome proﬁling. All urine samples (n = 6 per group and per
ime point) used for further validation by ELISA assays. Then six
ice per group and per time point were sacriﬁced at days 2, 7 and
0 to collect kidneys for histology and proteome proﬁling. At each
ime point mice were anesthetized using isoﬂurane and blood was
ollected via cardiac puncture before kidneys were removed, and
erum samples prepared and stored at −80 ◦C for later analyses
Fig. 1). Each kidney was cut longitudinally into two halves, one half
as snap-frozen in liquid nitrogen-cooled isopentane and stored at
80 ◦C for later molecular analyses while the other half was  ﬁxed
n 10% neutral formalin solution for histopathological analyses.
Additional urine samples were collected from mdx23 mice and
ge matched wild type C57BL/10 male mice (n = 12 per group) for
aseline urine AKI ELISA assay (Table 1).
Urine collection was done using a previously described method
30] with minor changes. Brieﬂy, individual mouse was placed in
lean cages without bedding, food or water for 4 h. Urine droplets
n the bottom of the cage were recovered, and transferred to
mall tubes and chilled. Average urine volume collected from each
ouse ranged from 100 L to 500 L. The collected urine samples
ere centrifuged at 14,000 × g for 5 min  at 4 ◦C. Supernatants were
able 1A
aseline urine ﬂow rate and analysis in wild type C57BL10 and mdx23 mice (mean ± SD)
Strain Age (weeks) Timed urine
collection (min)
Urine protein
(g/l)
C57BL10 (n = 12) 7 240 4.16 ± 1.44 
mdx23  (n = 12) 7 240 5.68 ± 1.04 
Folds  (mdx23/C57BL10) 1.37 
P  value 0.0466 
 < 0.05 is signiﬁcant.orts 2 (2015) 838–849
collected and stored in small volume aliquots (10 L) at −80 ◦C for
later analyses.
2.4. Measurement of PMO  excretion
To measure urinary excretion of PMO  we  used a mass spec-
trometry approach for analysis of 10 L urine aliquots collect
at 0, 30 min, 45 min, 60 min, 90 min, 120 min, 180 min, and
360 min  following injection of mdx-23 mice with single high
dose PMO  (800 mg/kg). Proteins were precipitated by addition of
200 l methanol, followed by 1 h incubation at room temperature.
Samples were then centrifuged for 10 min  at 14,000 × g and super-
natants containing the PMO  were saved. The pellet was  washed
with 100 l of 100 mM Tris, pH 7, then centrifuged again and
supernatants pooled. Supernatants containing PMO  were dried by
vacuum centrifugation in Reacti-vials then resuspended in 50 l of
water, heated for 5 min  at 60 ◦C and allowed to cool to room tem-
perature. The sample was  then processed using BioRad BioSpin 6
columns and Millipore C18 ZipTips using manufacturer’s instruc-
tions. The ZipTip eluent was  analyzed by static nanospray on
a Thermo OrbitrapXL at 100,000 resolution and 800–2000 m/z.
Spectra were deconvoluted using Thermo Xtract software. Signal
intensities of injected morpholino were plotted vs. time.
2.5. Measurement of urine creatinine, protein concentration and
serum urea nitrogen
Urine creatinine levels were measured using Creatinine Assay
Kit (R&D Systems, Minneapolis, MN)  based on the Jaffe alkaline
picrate method and following the manufacturer recommended
protocol. Serum urea nitrogen (SUn) was determined using
QuantiChromTM Urea Assay Kit (BioAssay System, Atlanta, GA)
following the manufacturer recommended protocol. To measure
protein concentration in collected urine samples, pre-cooled 40 l
distilled and deionized water (ddH2O) and 200 l of pre-chilled
acetone (overnight at −20 ◦C) were added to 10 L urine. The sam-
ple was vigorously mixed and incubated at −20 ◦C for 30 min,
then centrifuged at 14,000 × g 4 ◦C, for 15 min. Precipitated pro-
teins were resuspended in 40 l ddH2O and protein content was
measured using Pierce BCA assay (Thermo Scientiﬁc, Rockford,
IL). Protein excretion calculation formula: protein concentra-
tion × volume/minutes (4 h); urine output calculation formula:
total urine volume/minutes (4 h).
2.6. Renal histopathology
Formalin-ﬁxed kidneys (n = 6 per group and per time point) were
parafﬁn-embedded, and 4 micron sagittal sections cut and stained
with hematoxylin and eosin (H&E) or Periodic Acid Shift (PAS)
as previously described [31]. All slides were given a renal corti-
cal tubular injury score using a semi-quantitative scale [32–34].
Because of the exploratory nature of the study and the small
sample size, evaluation of kidney histology was performed in non-
blinded fashion. Ten microscopic ﬁelds were examined in each
section under 20× and 40× magniﬁcations for histological evidence
.
Urine creatinine
(mg/dl)
protein Excretion
(g/min)
Urine output (l/min)
37.07 ± 5.98 15.35 ± 2.40 3.33 ± 1.23
21.92 ± 2.55 34.13 ± 9.17 6.50 ± 1.76
0.59 2.25 1.95
<0.0001 <0.0001 <0.0001
A. Zhang et al. / Toxicology Reports 2 (2015) 838–849 841
Table  1B
Base line comparison of AKI urinary biomarkers in mdx23 and wild type C57BL10 mice (mean ± SD).
Strain Albumin (g/ml) KIM1 (pg/ml) Cystatin C (g/ml) Clusterin (g/ml) EGF (g/ml) NGAL (ng/ml) GGT1 (ng/ml) OPN (g/ml)
C57BL10 (n = 12) 36.34 ± 9.74 74.45 ± 2.86 0.10 ± 0.02 0.84 ± 0.27 0.81 ± 0.20 1.23 ± 0.58 11.30 ± 0.91 1.22 ± 0.33
mdx23  (n = 12) 75.97 ± 21.52 72.44 ± 4.99 0.13 ± 0.03 0.72 ± 0.17 0.48 ± 0.03 4.21 ± 0.73 11.69 ± 3.67 1.06 ± 0.29
Folds  (mdx23/C57BL10) 2.09 0.97 1.3 0.86 0.51 3.42 1.03 0.87
P  value <0.0001 >0.05 0.0175 >0.05 <0.001 <0.0001 >0.05 >0.05
A iderm
g
o
u
s
p
c
w
i
m
4
2
p
o
m
N
C
i
t
s
b
h
g
s
c
h
c
(
a
p
f
g
1
o
e
w
1
7
2
a
a
B
T
C
A
gbbreviations: AKI, acute kidney injury; KIM1, kidney injury molecule-1; EGF, pro-ep
lutamyltranspeptidase 1; OPN, osteopontin. P values < 0.05 are signiﬁcant.
f tubular injury, which included single or multiple tubular cells
ndergoing necrosis (deﬁned as nuclear condensation, cytoplasmic
welling, and focal loss of nuclei), tubular dilatation, microcysts,
roteinaceous cast, and recruitment of inﬂammatory cells. The per-
entage of the renal cortical area exhibiting any of these lesions
ere scored as followed: 0 = normal kidney, 1 = minimal tubular
njury < 5% involvement; 2 = mild tubular injury (6–20% involve-
ent); 3 = moderate tubular injury (21–50% involvement); and
 = severe tubular injury (>50% involvement).
.7. Proteomic proﬁling
Urine samples (15 L) from PMO  and saline treated mice (n = 1
er group and per time point) were each spiked with 7.5 L
f 15N labeled urine sample collected from 15N-labeled SILAM
ouse. Mixed samples were fractionated by SDS-PAGE using 4–12%
uPAGE® Novex® Bis-Tris gels. Gels were stained with Bio-Safe
oomassie blue (Bio-Rad, Hercules, CA), and each sample lane cut
nto 23–24 serial slices. Each gel slice was then in-gel digested with
rypsin (10–20 l 12.5 ng/l in 50 mM NH4HCO3) (Promega, Madi-
on, WI), and the resulting peptides were extracted and analyzed
y LC–MS/MS as described below.
Kidney tissue protein extraction and analysis was  done by
omogenization and lysis of the frozen samples in without deter-
ent lysis buffer (1 mM potassium phosphate monobasic, 3 mM
odium phosphate dibasic, 155 mM NaCl, Roche protease inhibitor
ocktail tablets, pH 7.4) using a motor-driven Potter-Elvehjem
omogenizer and sonication (Polytron, 3 × 30 s bursts). Protein
oncentration was determined in each sample using BCA assay
Thermo scientiﬁc, Rockford, IL). Each kidney protein extract (50 g
liquot) was spiked with 25 g of 15N labeled kidney protein extract
repared from a SILAM mouse. Spiked samples were then further
ractionated by SDS-PAGE as described above and processed for in
el digestion similarly as urine samples.
Peptide mixtures from each gel band were resuspended in
0 L of 0.1% formic acid and loaded (6 L) via an auto-sampler
nto a Symmetry C18 trap column (5 m,  300 m inner diam-
ter × 23 mm,  Waters Milford, MA). The trapped peptides were
ashed for 10 min  with 0.1% formic acid at a ﬂow rate of
0 L/min then eluted on a C18 reversed-phase column (3.5 m,
5 m × 15 cm,  LC Packings Sunnyvale, CA) at a ﬂow rate of
50 nL/min using a Nano-HPLC system from Eksigent (Dublin, CA)
nd a mobile phase consisting of water with 0.1% formic acid (A)
nd 90% acetonitrile (B). A 65-min linear gradient from 5% to 40%
 was employed. Eluted peptides were introduced into the mass
able 1C
reatinine normalization of base line comparison of AKI urinary biomarkers in mdx23 an
Strain Albumin (g/mg) KIM1 (ng/mg) Cystatin C (g/mg) Cl
C57BL10 (n = 12) 98.19 ± 21.50 0.20 ± 0.03 0.28 ± 0.04 2.2
mdx23  (n = 12) 384.22 ± 98.85 0.33 ± 0.03 0.60 ± 0.05 3.3
Folds  (mdx23/C57BL10) 3.91 1.65 2.14 1.4
P  value <0.0001 <0.0001 <0.0001 0.0
bbreviations: AKI, acute kidney injury; KIM1, kidney injury molecule-1; EGF, pro-epiderm
lutamyltranspeptidase 1; OPN, osteopontin. P values < 0.05 are signiﬁcant.al growth factor; NGAL, neutrophil gelatinase-associated lipocalin; GGT1, gamma-
spectrometer via a 10 m silica tip (New Objective Inc., Ringoes,
NJ) adapted to a nano-electrospray source (Thermo Fisher Scien-
tiﬁc). The spray voltage was set at 1.2 kV, and the capillary heated to
200 ◦C. The LTQ-Orbitrap-XL (Thermo Fisher Scientiﬁc) was oper-
ated in data-dependent mode with dynamic exclusion, in which
one cycle of experiments consisted of a full MS  survey scan in
the Orbitrap (300–2000 m/z, at 30,000 resolution) and ﬁve subse-
quent MS/MS  scans in the LTQ of the most intense peaks, using
collision-induced dissociation with helium gas and normalized col-
lision energy value set at 35%.
2.8. Database search and SILAM ratio measurement
For protein identiﬁcation and quantiﬁcation we used Inte-
grated Proteomics Pipeline (IP2) version 1.42 software devel-
oped by Integrated Proteomics Applications, Inc. (http://www.
integratedproteomics.com/). IP2 uses the Sequest search engine
version 2010 (06 10 13 1836). Each raw MS  and MS/MS  ﬁle
was searched against the forward and reverse UniProt mouse
database (UniProt release 15.15, January 2013, 16,580 forward
entries) tryptic peptides allowing two  missed cleavages and the
possible modiﬁcations of Met  residue by oxidation (+15.99492 Da)
and nitrogen atoms (+0.98 Da) to account for 15N labeled peptides.
Because of the wide isotope distribution of 15N labeled peptides
the mass tolerance was set at ±300 ppm (15 N) for MS  and ±1.5 Da
for MS/MS. Data were ﬁltered by setting the protein false discov-
ery rate (FDR) at 1%. Only proteins that were identiﬁed by at least
two unique peptides were retained for further quantitative analy-
sis. Census software (version 1.77), built into the IP2 platform, was
used to determine the ratios of light to heavy peptide pairs using an
extracted chromatogram approach. Quantitative data were ﬁltered
based on a determinant value of 0.5 and an outlier P-value of 0.1.
2.9. ELISA assays
Mouse speciﬁc osteopontin (OPN), pro-epidermal growth factor
(EGF), neutrophil gelatinase-associated lipocalin (NGAL), Kidney
Injury Molecule-1 (KIM-1), Cystatin C and clusterin ELISA assay
kits were purchased from R&D Systems, Inc. (Minneapolis, MN);
albumin ELISA kit was  from Bethy Laboratories, Inc. (Montgomery,
TX); and pancreatic amylase 2 (AMY2) and  glutamytrans-
ferase 1 (GGT-1) kits were from BlueGene, Biotech (Putuo District,
Shanghai). Urine aliquots (10 L) from each PMO  and saline treated
mouse at each time point were used in duplicate in each assay
following the manufacturer’s recommended protocols.
d wild type C57BL10 mice (mean ± SD).
usterin (g/mg) EGF (g/mg) NGAL (ng/mg) GGT1 (ng/mg) OPN (g/ml)
6 ± 0.63 2.17 ± 0.37 69.21 ± 31.31 31.20 ± 14.97 3.29 ± 0.71
0 ± 0.64 2.17 ± 0.32 384.0 ± 58.05 53.82 ± 19.60 4.81 ± 1.01
6 1 5.55 1.72 1.46
006 >0.05 <0.0001 0.0044 0.0003
al growth factor; NGAL, neutrophil gelatinase-associated lipocalin; GGT1, gamma-
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.10. Western blot analysis
Kidney protein-extracts (20 g aliquots) were fractionated by
DS-PAGE on 4–12% NuPAGE® Novex® Bis-Tris gels (Invitrogen,
rand Island, NY). Separated proteins were transferred to nitro-
ellulose membranes (Millipore, Billerica, MA,  USA) at 300 mA for
0 min  at room temperature. Membranes were blocked in TBS-T
20 mM Tris pH 7.5, 500 mM NaCl, 0.1% Tween 20) supplemented
ith 5% non-fat dry milk (Bio-Rad) for 1 h at room temperature.
lots were probed with the following primary antibodies: goat
nti-Aminopeptidase N (AP-N), goat anti-Meprin A subunit alpha
Mep-1) and rabbit anti-glutamyl aminopeptidase (AP-A) (R&D
ystem, 1:1000), rabbit anti-fatty acid binding protein heart type
FABPH) (1:200, Gene Tax), rabbit anti-11-fold increase in NADH
ehydrogenase [ubiquinone] 1 beta sub complex subunit 9 (CI-B22)
1:500, Gene Tax) and mouse anti-vinculin (1:2000, Cell Signaling)
ith the corresponding horseradish peroxidase-conjugated sec-
ndary antibody (1:5000–1:20,000 dilution). Blots were processed
sing an ECL detection kit (GE Life, Pittsburgh, PA) and exposed to
-ray ﬁlms. For quantiﬁcation, ﬁlms were scanned using a Bio-Rad
S-800 calibrated densitometer running Quantity One software
Bio-Rad). Optical density of each speciﬁc band was analyzed using
mage J Software..11. Statistical analyses
Unpaired two-tailed Student’s T test was used for simple two
roup assessments. Differences between mean value of PMO  and
ig. 2. (A) Histopathological changes in mdx-23 kidneys following single high dose PMO
ays  2, 7 and 30 following PMO  or saline treatment and stained with hematoxylin and eosi
f  kidney sections from representative sections. Black arrows indicate tubules that are d
he  more relevant renal tubular changes were observed at day 7 in PMO treated mouse 
tandard deviation obtained from renal cortical tubular injury scores using a semi-quanti
dx-23 mice (n = 6) at days 2, 7 and 30 following treatment of mdx-23 mice. Signiﬁcan
pparent at days 2 and 30 following treatment.orts 2 (2015) 838–849
saline groups, or among different time points were considered sig-
niﬁcant when the P < 0.05.
3. Results
3.1. Dystrophin deﬁcient mdx-23 mice develop spontaneous renal
injury and show changes in urinary biomarkers of AKI
Prior to determining the effects of high dose PMO  on the kid-
neys of the mdx-23 mouse model for DMD, we  assessed the baseline
renal status of these mice in comparison with age matched C57BL10
wild type control mice. Surprisingly, we  found that 7 week old male
mdx-23 mice develop signiﬁcant proteinuria (2.25 fold increase
over wild-type; P < 0.0001), and increased urine output (1.95 fold,
P < 0.0001) when compared to control mice (Table 1A). We  should
acknowledge however that the urine output was calculated based
on a 4 h collection period, which is a limited period to estimate the
total urine output. The urinary creatinine concentration in mdx-23
mice was  signiﬁcantly decreased relative to the wild type (Table 1A)
indicating a diluted urine output. Alternatively, the low urine creat-
inine concentration could be the reﬂection of the decreased muscle
mass, which is characteristic of the mdx-23 DMD  mouse model.
Other established markers of glomerular and tubular injury [35],
including albumin, Cystatin C, and NGAL (all expressed per ml
of urine) were signiﬁcantly increased in mdx mice relative to the
age matched WT  controls (2.1, 1.3, 3.4 fold respectively; P < 0.01)
(Table 1B). In addition, the urinary levels of EGF were decreased in
 injection (800 mg/kg). Sections were prepared from mdx-23 kidneys collected at
n stain. (Panel A) represents microscope examination (original magniﬁcation 400×)
ilated, shows signs of epithelial cell atrophy and attenuation, and/or degeneration.
but not in saline treated mouse. (Panel B) represent average quantitative data and
tative scale on kidney sections from PMO  treated mdx  23 (n = 6) and saline treated
t differences were observed only at day 7 following treatment (P = 0.03) and less
A. Zhang et al. / Toxicology Reports 2 (2015) 838–849 843
Table  2
Characteristics of mdx23 mice used in the study (mean ± SD).
Strain Duration (days) Treatment Age (weeks) SUn (mg/dL) Kidney/body (g/kg) Body weight (g)
mdx23 2 Saline (n = 6) 8 41.43 ± 7.17 7.91 ± 0.34 28.47 ± 1.68
PMO  (n = 6) 8 42.37 ± 5.37 7.78 ± 0.99 26.88 ± 3.09
7 Saline (n = 6) 7 44.89 ± 6.31 7.45 ± 0.22 25.13 ± 2.07
PMO  (n = 6) 7 46.01 ± 2.31 7.51 ± 0.41 25.34 ± 2.29
30 Saline (n = 6) 11 40.00 ± 3.23 6.51 ± 0.22 33.22 ± 2.2
PMO  (n = 6) 11 41.42 ± 3.77 6.62 ± 0.31 32 ± 1.76
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signiﬁcantly altered between PMO  treated and untreated groups.P  value 
Un (serum urea nitrogen), kidney to body weight, and body weight were not signi
dx-23 mice (2.0 fold decrease; P < 0.001; Table 1B), in agreement
ith the results of previous AKI studies [35]. Other established uri-
ary biomarkers of renal tubular injury, including NGAL, KIM-1,
ystatin C, clusterin, GGT1, and OPN, all expressed as a ratio of the
rinary creatinine values, were also signiﬁcantly increased in mdx-
3 mice relative to wild type mice (Table 1C). Even though KIM-1 is
 well-established AKI biomarker [36–38], the KIM-1 urinary levels
ere only moderately increased (1.6 fold) in the 7 week old mdx-23
ice, relative to wild type mice, and when compared to the changes
oted in NGAL levels (5.5 fold) under similar circumstances. We
peculate that these changes are induced by the release of muscle
roteins into the circulation that are ﬁltered in the kidney. NGAL
nd KIM-1 may  have different sensitivity to detect the chronic renal
njury changes induced by proteins released by injured muscles and
his is in agreement with previous report indicating that NGAL is
ore sensitive to AKI than KIM-1 [38]. However, further studies
re needed to test this hypothesis, by assessing changes in urinary
IM-1 and NGAL at several time points throughout the progression
f the muscle disease seen in mdx-23 mice. In summary, these data
ndicate that 7 weeks old male mdx-23 mouse develops sponta-
eous glomerular and tubular injury. Although the mechanism of
enal injury in the mdx-23 mouse is unclear at the present time, it
s tempting to speculate that these changes might be caused by the
elease of proteins into the circulation from injured muscles, such
s myoglobin, which are ﬁltered and accumulated in the kidney
29,39].
.2. Renal clearance and effect of high dose PMO  on the kidney
istology of mdx-23 mice
Mdx-23 mice injected with a single high dose PMO  (800 mg/kg)
evealed a rapid urinary clearance of the drug (supplemental Fig.
). PMO was detected in the urine as early as 30 min  following the
njections, and the peak urinary levels of PMO  were detected 1 h
ollowing the injections. These ﬁndings are in agreement with pre-
ious PK studies [40,41], which showed that the concentration of
MO  in the plasma decreases rapidly within the ﬁrst 30 min  after
njection, and that this drop in plasma levels is correlated with rapid
xcretion into the urine.
In agreement with the results of previous studies [6,12], we
ound that mdx-23 mice injected with 800 mg/kg of PMO  developed
ransient renal tubular injury. These lesions were characterized by
he presence of single or multiple cell necrosis in renal tubular
ells, and the development of mild tubular dilatation (Fig. 2), which
n many cases was associated with the recruitment of inﬂamma-
ory cells. A subset of PMO  treated mice (<15%) showed tubular
icro-cysts, and none of these mice developed proteinaceous cast.
sing standard renal injury histological scores, these changes were
tatistically signiﬁcant only in mice sacriﬁced 7 days after the
MO  injection, compared to the control mdx mice (P = 0.03), and
ere reversible approximately one month after the PMO  injection.
nterestingly, we did not ﬁnd signiﬁcant differences in the urinary
lbumin/creatinine ratio between PMO  and saline treated mdx23
ice (supplemental Fig. S1). These ﬁndings suggest that eitherP > 0.05 P > 0.05 P > 0.05
ly different between PMO  and saline treated mdx23 mice.
PMO  did not induce further glomerular injury, or alternatively, that
the pre-existing glomerular injury changes detected at baseline in
both groups may  affect the interpretation of the biomarker results
(Table 2).
3.3. Pilot screening of new candidate renal injury biomarkers
using SILAM proteome proﬁling of the kidneys of mdx-23 mice
injected with high dose PMO
Molecular correlates of high dose PMO-induced acute kidney
changes were identiﬁed using proteomics proﬁling (SILAM) in rep-
resentative pair of kidney samples (n = 1) collected at 2, 7 and 30
days after the PMO  or saline injection. As shown in the supple-
mental Table 1, 1446 proteins were identiﬁed and quantiﬁed by at
least two  unique peptides per protein in mouse kidney tissues. Of
the 1446 quantiﬁed proteins, 11 were found signiﬁcantly altered
in their levels, by two standard deviations of the average mean, in
the kidneys of PMO  treated-mice but not in the saline treated-mice.
These 11 proteins are listed with their ratios to internal stable iso-
tope labeled standards and fold change in PMO relative to saline
treated mouse across different time points (Table 3). Most of these
altered proteins were of mitochondrial origin, and involved in the
oxidative reduction pathways such as cytochrome c oxidase (Cyt-
cox), mitochondrial pyruvate carboxylase (PCB), 5-oxoprolinase
(5-OPase), mitochondrial aspartate aminotransferase (mAspAT),
and alpha-aminoadipic semialdehyde synthase (Aass). The expres-
sion of Annexin 2 (Anx2), a calcium-regulated membrane-binding
protein, was also increased following the PMO  treatment. All these
proteins increased by above 2-fold at days 2 and 7 in the kidney
of PMO  treated mice relative to the control mice, and returned
to control levels by day 30. Additional proteins showed a more
delayed response, increasing 7 days after the PMO  injection rela-
tive to saline; 11-fold increase in CI-B22; 3-fold increase in FABPH,
Mep-1, AP-N, and AP-A. These changes returned to baseline levels
by day 30.
Among the 11 proteins that were identiﬁed by the SILAM
screening, eight appear to be novel candidate biomarkers of renal
injury, whereas three (Mep-1, AP-N and AP-A) have been previously
associated with the damage of renal proximal tubules or other renal
structures [42–49]. These three proteins and other newly discov-
ered proteins, such as FABPH and CI-B22 were further veriﬁed by
western blot analysis in all PMO  treated and saline treated mice
(n = 6 per group and per time point) (Fig. 3). Vincula were used as
loading control, because they did not change in function of treat-
ment and across time points. The data show that Mep-1 was slightly
but signiﬁcant increase at day 2 (P < 0.05), while FABPH signiﬁcantly
decreased (P < 0.01) at days 2 and 30 in kidneys of PMO  treated
mdx  mice relative to saline treated mdx  mice. CI-B22 was notAttempts to evaluate other discovered PMO induced proteins in the
mdx  mouse kidney extract (e.g. Cutco, mitochondrial PCB, 5-OPase
and mitochondrial as pat) were not satisfactory due to poor quality
of the commercially available antibody for these mouse proteins.
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Table 3
List of proteins whose levels were signiﬁcantly altered in the kidneys as a function of time following treatment of mdx23 mouse with a single high dose PMO  (800 mg/kg) or saline solution alone.
Uniprot ID Description Day 2 Day 7 Day 30 Function
Saline PMO Fold
(PMO/saline)
Saline PMO  Fold
(PMO/saline)
Saline PMO  Fold
(PMO/saline)
Q8K010 5-OPase 1.96 ± 0.09 4.96 ± 0.13 2.5 2 ± 0.12 4.98 ± 0.28 2.49 2.44 ± 0.05 2.02 ± 0.4 0.83 Catalyzes 5-oxo-l-proline to
form l-glutamate, ATP to ADP
P00405  Cytcox 2.32 ± 0.6 5.56 ± 0.53 2.4 2.43 ± 0.2 7.52 ± 0.88 3.09 2.01 ± 0.17 3.6 ± 0.53 0.56 The component of the
respiratory chain
Q05920 PCB 2.94 ± 0.83 6.09 ± 0.48 2.1 3.35 ± 0.05 9.65 ± 0.25 2.74 3.17 ± 0.19 2.29 ± 0.02 0.58 ATP + pyruvate + HCO3− = ADP
+  phosphate + oxaloacetate
P05202  mAspAT 1.15 ± 0.06 2.31 ± 0.09 2 1.44 ± 0.07 4.3 ± 0.69 2.99 1.94 ± 0.15 1.1 ± 0.08 0.57 Metabolite exchange between
mitochondria and cytosol
Q99K67  Aass 1.54 ± 0.04 3.13 ± 0.3 2 1.63 ± 0.35 5.62 ± 0.48 3.45 2.9 ± 0.3 2.02 ± 0.09 0.70 Bifunctional enzyme
P07356  Anx2 1.37 ± 0.1 3.03 ± 0.3 2.21 1.24 ± 0 3.46 ± 0.11 2.79 3.83 ± 0.17 1.63 ± 0.12 0.44 Calcium-regulated
membrane-binding protein
P16858  GAPDH 1.29 ± 0.06 2.36 ± 0.19 1.83 1.59 ± 0.13 3.73 ± 0.27 2.35 1.72 ± 0.1 1.22 ± 0.05 0.71 playing a role in glycolysis and
nuclear functions
Q9CQJ8  CI-B22 2.11 ± 0.17 1.25 ± 2.9 0.78 0.89 ± 0.08 10.23 ± 0 11.49 2.92 ± 0.94 2.29 ± 0.06 0.59 Mitochondrial membrane
respiratory chain NADH
dehydrogenase (Complex I)
P11404  FABPH 2.22 ± 0 1.66 ± 0.02 1.08 0.44 ± 1.26 1.62 ± 0 3.68 1.93 ± 0.31 1.5 ± 0.09 0.74 A role in the intracellular
transport of long-chain fatty
acids and their acyl-CoA esters
P28825  MEP-1a 1.78 ± 0.2 2.12 ± 0.02 1.19 1.11 ± 0.98 3.55 ± 0.93 3.20 2.05 ± 0.23 1.53 ± 0.14 0.75 Kidney proximal tubules
intestinal brush borders and
salivary ducts
P97449  AP-Na 2.09 ± 0.07 3.47 ± 0.08 1.66 2.03 ± 0.36 6.61 ± 0.85 3.26 2.41 ± 0.22 1.66 ± 0.01 0.68 proximal convoluted tubules
P16406  AP-Aa 1.64 ± 0 3.07 ± 2.82 0.70 1.87 ± 0.22 6.51 ± 0.03 3.48 2.04 ± 0.03 1.43 ± 0.04 1.87 A role in the catabolic pathway
of the renin-angiotensin
system
Top row indicates the days after single injection of high dose PMO  or saline solutions. Abbreviations: 5-OPase for 5-oxoprolinase; Cytcox for Cytochrome c oxidase subunit 2; PCB for mitochondrial pyruvate carboxylase; mAspAT
for  mitochondrial aspartate aminotransferase; GAPDH for glyceraldehyde-3-phosphate dehydrogenase; Aass for alpha-aminoadipic semialdehyde synthase; Anx2 for annexin 2; CI-B22 for NADH dehydrogenase [ubiquinone] 1
beta  subcomplex subunit 9; FABPH for fatty acid binding protein heart type; AP-N for aminopeptidase N; AP-A for glutamyl aminopeptidase; Mep-1 for Meprin A subunit alpha; PMO: phosphorodiamidate morpholino oligomer.
Data  are presented as mean ± standard deviation of n = 1 per group and per time point. The means ± SD represent the average of light to heavy isotope ratio values obtained for all peptides detected for each protein in each sample.
a Known biomarkers associated with kidney injury.
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Table  4A
List of urinary proteins signiﬁcantly altered by LC–MS/MS with SILAM in their levels as a function of time following single high dose PMO  (800 mg/kg) or saline injection of
mdx-23  mouse.
Uniprot ID Description Day 1 Day 6 Day 29
Saline PMO  PMO/saline Saline PMO  PMO/saline Saline PMO  PMO/saline
P01132 EGF 2.65 ± 0.46 3.13 ± 0.21 1.18 0.93 ± 0.02 2.47 ± 0.15 #2.66 1.58 ± 0.07 1.68 ± 0.86 1.06
Q06890 Clusterin 2.15 ± 0.6 4.16 ± 0.16 #1.93 1.39 ± 0.13 1.72 ± 0.01 1.23 1.03 ± 0.21 1.15 ± 0.29 1.12
P00688 AMY2 2.19 ± 0 10.07 ± 1.3 #4.60 2.76 ± 0.01 2.83 ± 0.32 1.02 3.21 ± 0 3.37 ± 0.08 1.04
Q60928 GGT 1 x 3.82 Unique 0.88 ± 0.08 0.84 ± 0.01 0.95 0.98 ± 0.55 4.15 ± 0 #4.23
P97449 AP-N x 2.93 Unique 1.49 ± 0.02 1.6 ± 0.1 1.07 1.45 ± 0.04 3.16 ± 2.98 #2.17
Abbreviations:  EGF, epidermal growth factor; AMY2, pancreatic alpha-amylase; GGT1, gamma-glutamyltranspeptidase; AP-N, aminopeptidase N, X, not determined; PMO,
phosphorodiamidate morpholino oligomer. The means ± SD represent the average of light to heavy isotope ratio values obtained for all peptides detected for each protein in
each  sample; sample used n = 1.
# indicates detected urinary proteins increased fold ≥ .5 in PMO  vs saline.
Fig. 3. Western blot veriﬁcation of candidate proteins that were found altered in their levels in kidney proteome screening of PMO  treated mdx-23 mice relative to saline
treated  mice. Five protein candidates: Aminopeptidase N(AP-N), Meprin A subunit alpha (Mep-1), glutamyl aminopeptidase (AP-A), Fatty acid binding protein heart type
(FABPH), NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 [CI-B22] that were found altered in their levels in the kidneys of PMO treated mdx-23 mouse
kidney  relative to saline treated mdx-23 mouse (n = 6 per group and per time point) were targeted for western-blot analysis. (Panel 3A) shows immunochemical blot of all
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respectively in PMO  treated mouse relative to saline treated mouse.
Normalization to creatinine levels did not change the interpretation
of the data expressed as a ratio of the urinary creatinine concentra-
tion in fold changes (Table 4B).
Fig. 4. Subcellular localization of proteins identiﬁed in urine samples of mdx-23
mouse. An average of 147 proteins were identiﬁed and quantiﬁed in urine samplesroteins  (AP-A, AP-N, Mep-1, FABPH, CI-B22, and vinculin were used as loading con
ach  protein in each group and each time point, empty box represents saline treat
tandard error obtained from 6 samples. P values are indicated on the top of each g
0.
.4. Pilot screening of new candidate renal injury biomarkers
sing SILAM proteome of urine samples collected from mdx-23
ice injected with high dose PMO
For a more in depth pilot screening of new potential candi-
ate urinary biomarkers associated with the renal PMO  load and
learance, we performed SILAM proteome proﬁling on longitudinal
rine samples collected from mdx-23 mice at 1, 6 and 29 days after
 single dose of PMO  (800 mg/kg). Matched time series samples
rom saline injected mdx-23 mice were used as controls. A single
epresentative pair of treated and untreated mouse was randomly
hosen for each time point using the proteome proﬁling SILAM
pproach. In this discovery phase, 147 proteins were identiﬁed and
uantiﬁed across all mice and time points analyzed (supplemen-
al Table 2). The majority of proteins detected in urine were either
ecreted proteins (38% of total) or membrane-associated proteins
20%) (Fig. 4). Only 5 proteins among the 147 quantiﬁed urinary
roteins showed signiﬁcant alterations in their levels over time in
MO-injected mouse relative to saline injected mouse (Table 4A).
mong these, clusterin and AMY2 increased by 1.9 and 4.6 fold
espectively at day 1 in urine of PMO  treated mouse relative to
aline treated mouse, and then returned to normal levels at days
 and 29 following treatment. EGF increased at day 6 by 2.6 foldin each group and each time point. Panel 3B shows statistical box plots analysis for
up, and pattern box represents PMO  treated group. Each box indicates mean and
ep-1 signiﬁcantly increased at day 2, FABPH signiﬁcantly decreased at days 2 and
in PMO  treated mouse relative to saline treated mouse. At day
29 post treatment, AP-N and GGT1 increased by 2.2- and 4.2-foldfrom mdx-23 mice. Among these, 38% (56 proteins) were secreted proteins; 20%
(29  proteins) membrane origin; 9% (14 proteins) lysosomal origin, 3% (4 proteins)
ER/Golgi origin; 9% (13 proteins) nucleus origin, 11% (16 proteins) cytosolic, and
10% (15 proteins) of unspeciﬁed origin. Subcelular localization was retrieved from
Uniprot knowledge database.
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Fig. 5. Evaluation of biomarkers associated with PMO  renal load and clearance in urine samples of single high dose PMO  injected mdx-23 mice. Potential urinary biomarkers
associated with PMO  renal load and clearance that were identiﬁed by differential proteome proﬁling of urine samples collected at days 1, 6, 14 and 29 following treatment of
mdx-23 with single high dose PMO  (800 mg/kg) or saline solution alone were targeted for an evaluation, using ELISA assays, in all PMO  and saline treated mdx-23 (n = 6 per
group  and per time point). (A) Plots are shown from top row to bottom left to right for clusterin, GGT1 (gamma  glutamyltranspeptidase 1), EGF (pro-epidermal growth factor),
a three k
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Pnd  AMY2 (pancreatic alpha-amylase) discovered in this study. (B) Shows plots for 
ipocalin) and KIM-1 (Kidney Injury Molecule-1). All data were normalized by urine
aline  treated group (empty triangles) are indicated by * or ** on the top of each plo
These results were further veriﬁed in urine samples collected
rom all mdx-23 mice injected with either with PMO  or saline (n = 6
er group and per time point) using well established ELISA assays.
nly clusterin and GGT1 were found signiﬁcantly increased at days
 and 6 respectively in the PMO  treated group relative to the con-
rol group (Fig. 5A). Interestingly, targeted analysis by ELISA assay
f some known AKI biomarkers that we found already elevated in
rine of mdx-23 mice relative to wild type mice at baseline (see
ata above Tables 1B and 1C) did not show any further increase in
MO injected mdx-23 mice relative to saline injected mdx  controls
able 4B
old change of selected urinary biomarkers in PMO  treated relative to saline treated
dx-23 mice in Table 4A after normalization to creatinine levels.
UniProt ID Description Day 1 Day 6 Day 30
PMO/Saline PMO/saline PMO/saline
P01132 EGF 1.29 a3.82 0.69
Q06890 Clusterin a2.11 a1.71 0.72
P00688 AMY2 a5.00 1.38 0.68
Q60928 GGT1 Unique 1.17 a2.74
P97449 AP-N Unique a1.5 1.41
a Biomarkers increased in PMO  treatment, folds > 1.5. Unique: only determined in
MO.nown AKI biomarkers including Albumin, NGAL (Neutrophil gelatinase-associated
inine levels. Signiﬁcant differences between PMO  treated group (solid squares) and
 respective Ps.
(Fig. 5B). Given the pre-exiting renal injury detected at baseline
in all mdx-23 mice, our ﬁndings suggest that clusterin and GGT1
might be speciﬁc candidate biomarkers to detect the PMO-induced
renal tubular injury, even in the context of underlying renal dam-
age.
4. Discussion
The mdx-23 mouse model has been utilized extensively to study
the pathogenesis and treatment of DMD, including pre-clinical
studies of therapeutic oligonucleotide-induced exon skipping of
the DMD gene to restore dystrophin protein expression in muscle
[50,51]. Because previous pre-clinical studies showed that this gene
therapy approach can cause renal tubular injury [6,12], we  carried
out this pilot study to identify new candidate urinary biomarkers
of AKI in the mdx-23 mouse injected with high dose PMO, using a
proteomic proﬁling SILAM-approach. Surprisingly, we  found that
adult mdx-23 mice developed spontaneous renal injury indepen-
dently of the PMO  injection. These changes were manifested by
albuminuria, increased urine output, and changes in several estab-
lished urinary biomarkers of acute kidney injury (AKI). Nonetheless,
a single high dose PMO  injection induced further renal tubular
injury in 7 week old mdx-23 mice, which peaked at 7 days, and
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eturned to the baseline levels at 30 days. The SILAM approach
dentiﬁed speciﬁc changes in the expression of several proteins,
ncluding Mep-1 in kidneys, clusterin and GGT1 in urine, which
ere validated by Western blots or ELISA and may  become promis-
ng candidate biomarkers to monitor the renal outcome of patients
ith DMD in future human clinical trials.
As discussed above, we sought to identify potential urinary
iomarkers to monitor the accumulation of oligonucleotides in
roximal tubules of mice that could be transitioned to clini-
ally useful biomarkers in human clinical trials of therapeutic
ligonucleotides drug treatments. Unfortunately we were unable
o compare other oligonucleotides containing the phosphorothio-
te backbone chemistry because of the toxicity of these molecules
hen given at high doses. One remarkable ﬁnding of our study was
he discovery of pre-existing renal injury in the mdx-23 mouse,
elative to the wild type control mouse. These ﬁndings should be
aken into consideration to interpret the results and to determine
heir clinical translational value of our ﬁndings for patients with
MD. More speciﬁcally, in the urinary proteome of the mdx-23
ouse at baseline, we found elevated levels of albumin, cystatin
, NGAL, and increased urine output. Although the mechanisms
esponsible for the renal injury are not understood at the present
ime, there are two possible interpretations of these data. First,
t is possible that dystrophin-deﬁciency in kidney cells directly
nduces kidney dysfunction, leading to proteinuria in the mdx-23
ice [52,53]. Indeed, dystrophin is expressed in smooth muscle,
ncluding vascular smooth muscle [52,53], and the dystrophin-
ystroglycan complex may  play a role in maintaining vasculature
nd kidney function [54]. Second, dystrophin is best characterized
s an important component of the myoﬁber membrane cytoskele-
on in skeletal muscle. Its lack of expression in Duchenne leads to
uscle tissue damage and high protein loads of muscle-derived
omponents, such as creatine kinase and myoglobin into blood cir-
ulation. Furthermore, extensive muscle damage (rhabdomyolysis)
eads to myoglobinurea and can cause severe acute kidney dam-
ge with subsequent kidney failure. It is plausible that the chronic
eakage of myoﬁber components from muscle tissue into blood in
he mdx-23 mouse model leads to a chronic mild kidney damage
nd the proteinuria we  describe. The reported susceptibility of both
MD  patients and the mdx-23 mouse to bouts of myoglobinuria
ay  be consistent with this model [55]. These two models are not
utually exclusive. We  note that kidney failure is not a typical fea-
ure of Duchenne muscular dystrophy or the mdx  mouse model.
hus, it appears that the changes detected are not progressive.
urther studies are needed to explore the pathogenesis of these
esions.
It is worth mentioning that the dose of PMO  utilized in our study
as 16–25 times higher than the doses used in clinical trials [13,14].
his PMO dose induced transient renal tubular histological changes,
hich peaked 7 days after injection, without causing acute renal
ailure, and returned to baseline levels 30 days after the injection.
hese data are in agreement with the results of previous studies
one in mdx  mice injected weekly with high dose PMO  (960 mg/kg)
or up to 12 weeks [6]. Interestingly, several biomarkers of AKI that
ere increased at baseline in the urine of mdx  mice relative to wild
ype mice, remained unchanged in PMO-treated mice throughout
he study time points (e.g. 1, 6, 14 and 29 days). It is possible that the
enal injury changes detected at baseline, which were not homoge-
ous in all mice, could affect our ability to interpret the biomarker
esults. Nonetheless, the SILAM data together with the renal his-
ological ﬁndings indicate that PMO  induced further renal tubular
njury, which is transient and appears to be reversible.Query of the molecular proﬁles of both the kidney and urinary
roteome found a limited number of PMO-induced changes that
ould be associated with the transient oligonucleotide accumula-
ion in renal tubular cells. The clinical relevance of these ﬁndings fororts 2 (2015) 838–849 847
patients receiving PMO  therapy is unclear, since the murine dose
administered was  over 25 fold higher than the expected human
dose given in the clinic. In the kidney, we  observed changes in
known AKI associated proteins such as Mep-1 [42–44] at day 2
(P < 0.05), and FABPH [56–59] at day 7 even though not signiﬁcant
(Fig. 3B, P = 0.06). These changes occurred as early as day 2 follow-
ing PMO  injection, and before the most severe renal histological
changes were detected in mice treated with PMO. Finally, the pro-
teomic proﬁling SILAM approaches in kidney samples shows that
all these changes returned to baseline levels 30 days after the PMO
injection.
In the urinary proteome, of the 147 quantiﬁed proteins only
clusterin and GGT1 showed signiﬁcant alterations both via pro-
teomics and ELISA evaluation. Other known AKI biomarkers did
not show a PMO-induced increase in urine. While clusterin was
increased in urine of PMO  treated mdx  mice as early as 24 h post
treatment, GGT1 was increased at day 6 post treatment. Both pro-
teins returned to normal levels at day 14 following treatment.
Clusterin is a secreted chaperone protein that is involved in the
regeneration and proliferation of tubular epithelial cells, progres-
sion of the cell cycle, and reparation of DNA damage [60–62].
Increased levels of urinary clusterin have been reported to be a sen-
sitive and speciﬁc marker to monitor drug-induced insults on renal
tubules [63]. This early increase in clusterin expression was asso-
ciated with later tubular recovery, as evidenced by experiments
performed on clusterin KO mice vs. wild type mice. Taken together,
these ﬁndings suggest that urinary clusterin could be used as read-
out to monitor both kidney insult and recovery.
GGT1, a tubular brush border enzyme, was shown in this study
to be elevated in the urine of PMO  treated mice, relative to saline
treated mice at day 6 by ELISA assays. This data is in agreement with
previous studies where it has been shown that the urinary levels
of GGT1 increased immediately after kidney ischemia-reperfusion
insult, and then declined with time with other AKI biomarkers
[64–66]. Other studies have used urinary levels of GGT1 as an indi-
cator of proximal tubular injury in rats injected with high doses of
colistin [67] or cisplatin [68]. Our ﬁnding that GGT1 increased in
urine at day 6 post injection in PMO  treated mice relative to saline
treated mice correlated with the changes seen in the morphology
of proximal tubules that occurred at day 7 in PMO  treated mice and
is in agreement with previous studies above. Interestingly, urinary
GGT1 returned to normal levels at 14 days following PMO  injection
and even decreased by almost 2 fold at day 29 when compared to
the urinary levels detected in saline treated mdx mice. According
to efﬁciency study of morpholino-induced exon skipping [50] in
mdx  mice, it showed dystrophin restoration and muscle improve-
ment at about day 14 following PMO  treatment. It is plausible that
recovery of PMO  treated mdx  mice from muscular dystrophin imply
less muscle necrosis and thus less stress on kidneys and thus GGT1
was further decreased in PMO  rescued mdx-23 relative to saline
treated mdx-23. However this hypothesis remains to be veriﬁed
using different PMO  regimens and efﬁcacy studies.
Even though the increase in the urine levels of clusterin and
GGT1 was  moderate at days 1 and 6 respectively in PMO  relative to
saline treated group these alterations could still serve as marker to
monitor PMO  kidney load. However, these preliminary data need
to be validated in future studies using chronic treatment of PMO
for longer period and in larger sample size.
5. ConclusionsIn summary, we  found that mdx-23 mice can develop spon-
taneous renal injury, and that these changes may  affect the
identiﬁcation of new biomarkers, as well as the outcome of mice
treated with PMO. Nonetheless, using a combination of the SILAM
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ubular injury. Previous studies [41], including our current data,
how that urinary PMO  clearance occurs immediately after injec-
ion and peaks at about 1 h post injection. Urinary levels of clusterin
ollowed the PMO  clearance trend. It increased in urine during the
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n previous studies [61] while increased levels of GGT1 seems to
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